Sinonasal Tract Osteochondromyxoma: Future Directions Beyond Morphologic Description

The recent delineation of sinonasal tract osteochondromyxoma (STOX) as a distinct entity, characterized by PRKAR1A inactivation and association with Carney complex, represents a significant step forward in head and neck pathology (Bishop in Head Neck Pathol 19(1):117, 2025).

While the diagnostic criteria proposed by Bishop et al. are valuable, several substantive limitations necessitate scrutiny. The morphologic overlap with nasal chondromesenchymal hamartoma (NCMH) remains a formidable diagnostic challenge in small biopsies, and the reliance on PRKAR1A immunohistochemistry requires rigorous validation regarding its sensitivity and specificity, particularly in decalcified specimens. The study's characterization of the tumor's "locally aggressive" behavior lacks granularity, leaving critical management questions-such as optimal surgical margins and the potential for molecularly targeted therapies-unanswered. Furthermore, the vital link to Carney complex is not translated into a structured framework for interdisciplinary patient management and genetic counseling.

To transition from pathologic description to clinical impact, future efforts must focus on validating diagnostic criteria in large, multi-institutional cohorts, integrating comprehensive molecular profiling to uncover therapeutic vulnerabilities, and establishing evidence-based management protocols. The pathologic recognition of STOX must be seamlessly connected to systematic genetic evaluation and long-term monitoring, fulfilling the translational imperative of this diagnosis.